<DOC>
	<DOCNO>NCT02686294</DOCNO>
	<brief_summary>The purpose study assess pharmacokinetic characteristic bepotastine multiple oral administration TALION tab. , IR formulation bepotastine reference drug HL151 , SR formulation bepotastine test drug healthy male adult . Additionally safety tolerability two drug evaluate .</brief_summary>
	<brief_title>Repeated Dosing Clinical Trial HL151</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<criteria>1 . Healthy male age 1945 2 . Body weight ≥ 50kg , BMI 18~29 kg/m2 3 . Subject sign inform consent form willingly 1 . Subject serious active cardiovascular , respiratory , hepatologic , renal , hematologic , gastrointestinal , immunologic , dermal , neurologic , psychological disease history disease 2 . Subject acute disease within 28 day prior study medication dose 3 . Subject known history disease affect absorption , distribution , metabolism , excretion drug 4 . Subject clinically significant chronic disease 5 . Positive test HBs Ag , antiHCV Ab , antiHIV Ab , VDRL 6 . Use prescription medication within 14 day prior study medication dose 7 . Use medication overthecounter medication include oriental medication within 7 day prior study medication dose 8 . Subject clinically significant allergic disease 9 . Subject know hypersensitivity reaction bepotastine 10 . Subject follow condition laboratory test AST/ALT &gt; UNL ( upper normal limit ) x 2 Total bilirubin &gt; UNL x 2 Renal failure CLcr &lt; 50mL/min calculated CockcroftGault [ CockcroftGault GFR = ( 140age ) * ( Wt kg ) / ( 72 *Cr ) ] SBP &lt; 100mmHg ≥160mmHg , DBP &lt; 60mmHg ≥100mmHg QTc &gt; 440msec ECG Serum potassium &lt; 3.5 mEq/L &gt; 5.5 mEq/L 11 . Immunological incompetence , immune deficiency take immunosuppressant 12 . Subject take standard meal 13 . Subject whole blood donation within 60days , component blood donation within 20days prior study medication dose 14 . Subject blood transfusion within 30days prior study medication dose 15 . Participation clinical investigation within 90days prior study medication dose 16 . Continued excessive use caffeine ( caffeine &gt; five cups/day ) , alcohol ( alcohol &gt; 30g/day ) severe heavy smoker ( cigarette &gt; 10 cigarette per day ) 17 . Subject decision nonparticipation investigator 's review due laboratory test result excuse nonresponding request instruction investigator 18 . Subject take inducer inhibitor drug metabolism enzyme barbital within 30days prior study medication dose 19 . Subject use adequate mean contraception 20 . Subject genetic problem galactose intolerance , Lapp Lactase Deficiency glucosegalactose malabsorption 21 . Subject history drug abuse drug addiction</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>